Full Breakdown
EMA Recommends New Treatments for Small Cell Lung Cancer and Other Conditions
3/28/2026, 12:12:45 PM
Overview of Recent Recommendations
During its March 2026 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended five new medicines for approval, including two significant treatments for small cell lung cancer (SCLC). The committee granted a conditional marketing authorization for Adstiladrin (nadofaragene firadenovec) for non-muscle invasive bladder cancer and positive opinions for Imdylltra (tarlatamab) and Zepzelca (lurbinectedin) for SCLC.
New Treatments for Small Cell Lung Cancer
Imdylltra, developed by Amgen, is a targeted immunotherapy that addresses an unmet medical need for adults with relapsed extensive-stage SCLC. The CHMP emphasized that this treatment is crucial for patients with poor prognosis and limited options. In clinical trials, Imdylltra demonstrated a median overall survival of 13.6 months compared to 8.3 months for standard chemotherapy, representing a 40% reduction in the risk of death.
Zepzelca, produced by PharmaMar, is indicated for maintenance treatment in patients whose disease has not progressed after initial therapy. It has shown improved progression-free survival when used in combination with atezolizumab compared to atezolizumab alone.
Additional Medicines Recommended
The CHMP also recommended Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immune condition, and Bopediat (furosemide) for treating edema and hypertension in children. Furthermore, the committee endorsed extensions of therapeutic indications for 13 existing medicines, including Besponsa and Tafinlar.
Re-examination Outcomes
In a re-examination, the CHMP confirmed its refusal to extend the marketing authorization for Hetlioz (tasimelteon) to treat nighttime sleep disturbances in patients with Smith-Magenis syndrome. Additionally, an application for Blarcamesine, intended for Alzheimer’s disease, was withdrawn.
Official Statements & Responses
The CHMP highlighted the importance of new treatment options for SCLC, noting the limited efficacy of existing therapies after relapse. The committee's recommendations reflect ongoing efforts to address significant medical needs in oncology and rare diseases.
Criticism & Opposition
While the CHMP's recommendations are generally welcomed, some experts express concerns regarding the long-term efficacy and safety profiles of new treatments like Imdylltra and Zepzelca, particularly given the serious side effects associated with these therapies.
What's Next
The EMA will publish the minutes of the March 2026 meeting in the coming weeks, providing further insights into the discussions and decisions made regarding these new treatments and their implications for patient care in Europe.
Verbatim Quotes
- “The CHMP said the treatment provides a new targeted immunotherapy approach for these patients.” — CHMP
- “Outcome of re-examination After re-examining its initial opinion, the committee confirmed its recommendation to refuse a change to the marketing authorisation for Hetlioz (tasimelteon).” — CHMP
